Research ExplorerPublicationsOutcome after neoadjuvant chemotherapy in estrogen receptor-...

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

Standard

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. / van Mackelenbergh, Marion T; Denkert, Carsten; Nekljudova, Valentina; Karn, Thomas; Schem, Christian; Marmé, Frederik; Stickeler, Elmar; Jackisch, Christian; Hanusch, Claus; Huober, Jens; Fasching, Peter A; Blohmer, Jens-Uwe; Kümmel, Sherko; Müller, Volkmar; Schneeweiss, Andreas; Untch, Michael; von Minckwitz, Gunter; Weber, Karsten E; Loibl, Sibylle.

In: BREAST CANCER RES TR, Vol. 167, No. 1, 01.2018, p. 59-71.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

van Mackelenbergh, MT, Denkert, C, Nekljudova, V, Karn, T, Schem, C, Marmé, F, Stickeler, E, Jackisch, C, Hanusch, C, Huober, J, Fasching, PA, Blohmer, J-U, Kümmel, S, Müller, V, Schneeweiss, A, Untch, M, von Minckwitz, G, Weber, KE & Loibl, S 2018, 'Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials', BREAST CANCER RES TR, vol. 167, no. 1, pp. 59-71. https://doi.org/10.1007/s10549-017-4480-5

APA

van Mackelenbergh, M. T., Denkert, C., Nekljudova, V., Karn, T., Schem, C., Marmé, F., Stickeler, E., Jackisch, C., Hanusch, C., Huober, J., Fasching, P. A., Blohmer, J-U., Kümmel, S., Müller, V., Schneeweiss, A., Untch, M., von Minckwitz, G., Weber, K. E., & Loibl, S. (2018). Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. BREAST CANCER RES TR, 167(1), 59-71. https://doi.org/10.1007/s10549-017-4480-5

Vancouver

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. BREAST CANCER RES TR. 2018 Jan;167(1):59-71. https://doi.org/10.1007/s10549-017-4480-5

Bibtex

@article{0f6c47eab448467db90f089b2c7dc5d0,
title = "Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials",
abstract = "PURPOSE: The estrogen receptor (ER) is involved in control of progesterone receptor (PgR) expression and lack of PgR may be also a surrogate of altered growth factor signaling. The aim of this study was therefore to investigate PgR expression as predictive factor for response to neoadjuvant therapy and long-term outcome.METHODS: Five thousand and six hundred and thirteen patients with primary breast cancer and positive ER expression from ten German neoadjuvant trials of anthracycline and taxane-based chemotherapy were included. Pathologic complete response (pCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and local recurrence-free survival (LRFS) were compared according to PgR expression.RESULTS: The lack of PgR expression (1172 patients) was associated with grade 3 (38.4 vs. 26.3%; p < 0.001), nodal involvement (>cN2) (6.8% vs. 4.7%; p = 0.004), and HER2 positivity (36.2 vs. 22.3%; p < 0.001). pCR rates of PgR-negative tumors were higher in the entire cohort (13.8 vs. 7.5%; p < 0.001) and in the HER2-negative subgroup (11.2 vs. 5.8%; p < 0.001). In multivariable logistic regression, PgR negativity was an independent predictive factor for pCR overall (OR 1.76; p < 0.001) and in the HER2-negative patients (OR 1.99; p < 0.001). Patients with PgR-negative disease had significantly worse outcome (p < 0.001, respectively). Multivariable Cox regression analysis revealed that PgR was an independent prognostic factor for DFS, OS, DDFS, and LRFS.CONCLUSION: ER-positive/PgR-negative breast carcinomas are associated with higher response but also worse long-term outcome after neoadjuvant therapy. PgR negativity is an independent predictive factor for pCR after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.",
keywords = "Journal Article",
author = "{van Mackelenbergh}, {Marion T} and Carsten Denkert and Valentina Nekljudova and Thomas Karn and Christian Schem and Frederik Marm{\'e} and Elmar Stickeler and Christian Jackisch and Claus Hanusch and Jens Huober and Fasching, {Peter A} and Jens-Uwe Blohmer and Sherko K{\"u}mmel and Volkmar M{\"u}ller and Andreas Schneeweiss and Michael Untch and {von Minckwitz}, Gunter and Weber, {Karsten E} and Sibylle Loibl",
year = "2018",
month = jan,
doi = "10.1007/s10549-017-4480-5",
language = "English",
volume = "167",
pages = "59--71",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

AU - van Mackelenbergh, Marion T

AU - Denkert, Carsten

AU - Nekljudova, Valentina

AU - Karn, Thomas

AU - Schem, Christian

AU - Marmé, Frederik

AU - Stickeler, Elmar

AU - Jackisch, Christian

AU - Hanusch, Claus

AU - Huober, Jens

AU - Fasching, Peter A

AU - Blohmer, Jens-Uwe

AU - Kümmel, Sherko

AU - Müller, Volkmar

AU - Schneeweiss, Andreas

AU - Untch, Michael

AU - von Minckwitz, Gunter

AU - Weber, Karsten E

AU - Loibl, Sibylle

PY - 2018/1

Y1 - 2018/1

N2 - PURPOSE: The estrogen receptor (ER) is involved in control of progesterone receptor (PgR) expression and lack of PgR may be also a surrogate of altered growth factor signaling. The aim of this study was therefore to investigate PgR expression as predictive factor for response to neoadjuvant therapy and long-term outcome.METHODS: Five thousand and six hundred and thirteen patients with primary breast cancer and positive ER expression from ten German neoadjuvant trials of anthracycline and taxane-based chemotherapy were included. Pathologic complete response (pCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and local recurrence-free survival (LRFS) were compared according to PgR expression.RESULTS: The lack of PgR expression (1172 patients) was associated with grade 3 (38.4 vs. 26.3%; p < 0.001), nodal involvement (>cN2) (6.8% vs. 4.7%; p = 0.004), and HER2 positivity (36.2 vs. 22.3%; p < 0.001). pCR rates of PgR-negative tumors were higher in the entire cohort (13.8 vs. 7.5%; p < 0.001) and in the HER2-negative subgroup (11.2 vs. 5.8%; p < 0.001). In multivariable logistic regression, PgR negativity was an independent predictive factor for pCR overall (OR 1.76; p < 0.001) and in the HER2-negative patients (OR 1.99; p < 0.001). Patients with PgR-negative disease had significantly worse outcome (p < 0.001, respectively). Multivariable Cox regression analysis revealed that PgR was an independent prognostic factor for DFS, OS, DDFS, and LRFS.CONCLUSION: ER-positive/PgR-negative breast carcinomas are associated with higher response but also worse long-term outcome after neoadjuvant therapy. PgR negativity is an independent predictive factor for pCR after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

AB - PURPOSE: The estrogen receptor (ER) is involved in control of progesterone receptor (PgR) expression and lack of PgR may be also a surrogate of altered growth factor signaling. The aim of this study was therefore to investigate PgR expression as predictive factor for response to neoadjuvant therapy and long-term outcome.METHODS: Five thousand and six hundred and thirteen patients with primary breast cancer and positive ER expression from ten German neoadjuvant trials of anthracycline and taxane-based chemotherapy were included. Pathologic complete response (pCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and local recurrence-free survival (LRFS) were compared according to PgR expression.RESULTS: The lack of PgR expression (1172 patients) was associated with grade 3 (38.4 vs. 26.3%; p < 0.001), nodal involvement (>cN2) (6.8% vs. 4.7%; p = 0.004), and HER2 positivity (36.2 vs. 22.3%; p < 0.001). pCR rates of PgR-negative tumors were higher in the entire cohort (13.8 vs. 7.5%; p < 0.001) and in the HER2-negative subgroup (11.2 vs. 5.8%; p < 0.001). In multivariable logistic regression, PgR negativity was an independent predictive factor for pCR overall (OR 1.76; p < 0.001) and in the HER2-negative patients (OR 1.99; p < 0.001). Patients with PgR-negative disease had significantly worse outcome (p < 0.001, respectively). Multivariable Cox regression analysis revealed that PgR was an independent prognostic factor for DFS, OS, DDFS, and LRFS.CONCLUSION: ER-positive/PgR-negative breast carcinomas are associated with higher response but also worse long-term outcome after neoadjuvant therapy. PgR negativity is an independent predictive factor for pCR after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

KW - Journal Article

U2 - 10.1007/s10549-017-4480-5

DO - 10.1007/s10549-017-4480-5

M3 - SCORING: Journal article

C2 - 28875243

VL - 167

SP - 59

EP - 71

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 1

ER -